AAN 2021 | Tolebrutinib reduces new MRI lesions in highly active relapsing MS

Tolebrutinib is a novel selective Bruton tyrosine kinase inhibitor under investigation for the treatment of multiple sclerosis (MS). The small molecule inhibitor is highly central nervous system (CNS)–penetrant, allowing it to modulate CNS-resident immune cells. Anthony Traboulsee, MD, University of British Columbia Hospital, Vancouver, Canada, shares the results of a subgroup analysis of a Phase IIb study of 12-week tolebrutininb treatment (NCT03889639) in patients with highly active relapsing MS. The analysis found that tolebrutininb effectively prevented new MRI lesions in the high-risk subgroup, consistent with the results of the overall population. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.